ELYM News and Press, Eliem Therapeutics Inc From 08/02/22

Eliem Therapeutics ELYM -25% on report to discontinue development of lead asset as mid-stage pain trial fails . Mobile Global Esports (MGAM) -14% . Senti Biosciences ( SNTI ) -10% . Celyad Oncology ( CYAD ) -11% . Eos Energy Enterprises EOSE...

Clinical-stage biotech Eliem Therapeutics ( NASDAQ: ELYM ) announced on Tuesday that the company decided to discontinue further development of its lead asset ETX-810 after the failure of a mid-stage trial for the candidate in lumbosacral radicular pain (LSRP). The primary ...

SEATTLE and CAMBRIDGE, United Kingdom, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Eliem Therapeutics , Inc. (Nasdaq: ELYM), a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epileps...

Gainers: ToughBuilt Industries ( TBLT ) +53% . Yoshitsu ( TKLF ) +39% . Hanger ( HNGR ) +25% . Eve Holding ( EVEX ) +21% . Community Health Systems ( CYH ) +19% . Tabula Rasa HealthCare ( TRHC ) +12% . Rockwell Me...

Initiating a Phase 1 pharmacokinetics trial of ETX-155 to enable a Phase 2a trial in MDD planned to commence in first quarter of 2023 Sufficient capital expected to fund operations until mid-2024 SEATTLE and CAMBRIDGE, United Kingdom, July 18, 2022 (GLOBE NEWSWIRE) -- El...

Get ahead of the market by subscribing to Seeking Alpha's Stocks to Watch, a preview of key events scheduled for the coming week. The newsletter keeps you informed of the biggest stories set to make headlines, including upcoming IPOs, investor days, earnings reports and conference presentat...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due t...

SVB Leerink on Monday cut its price target on Eliem Therapeutics ( NASDAQ: ELYM ) to $9 from $13. The new PT - based on an SOTP analysis that forecasts cash flows into early 2040s, with 11% discount rate - implies potential upside of 142.6% to ELYM's last close. The b...

SEATTLE and CAMBRIDGE, United Kingdom, July 07, 2022 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM), a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and...

Topline data from the Phase 2a clinical trial are expected in the third quarter of 2022 Virtual investor event to be held in July 2022 SEATTLE and CAMBRIDGE, United Kingdom, June 27, 2022 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc., a clinical-stage biotechnology company ...